ProCE Banner Activity


HBV Treatment During Pregnancy: Mind the Gap


In this Medical Minute, learn from Dr Seng Gee Lim about strategies to prevent HBV mother-to-child transmission (MTCT) among infants born to HBsAg-positive mothers, including risk factors for MTCT, comparison of antiviral therapies, whom to treat, and prevention strategies for the infant.

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: April 11, 2024

Expiration: April 10, 2025



Seng Gee Lim

Seng Gee Lim, Professor, MBBS, FRACP, FRCP, MD, FAMS, FAASLD

Director of Hepatology
Division of Gastroenterology and Hepatology
National University Health System
Yong Loo Lin School of Medicine
National University of Singapore

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians, pharmacists, nurses, and other HCPs who care for patients with HBV.

Program Learning Goal

The goal of this activity is to improve learners’ competence in identifying candidates for HBV and HDV therapy and monitoring and managing individuals with HBV and HDV infections.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select an appropriate treatment regimen for each patient with HBV infection, with or without HDV infection, based on individualized application of clinical practice guidelines


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Seng Gee Lim, Professor, MBBS, FRACP, FRCP, MD, FAMS, FAASLD

Director of Hepatology
Division of Gastroenterology and Hepatology
National University Health System
Yong Loo Lin School of Medicine
National University of Singapore

Seng Gee Lim, Professor, MBBS, FRACP, FRCP, MD, FAMS, FAASLD: consultant/advisor/speaker: Abbott Labs, Arbutus, Assembly, Gilead Sciences, GlaxoSmithKline, Grifols, Roche, Sysmex; other (research materials): Abbott Labs, Gilead Sciences, Roche, Sysmex.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 11, 2024, through April 10, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-106-H01-P

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.